SynthesisCancer medicine2021
Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Synthesis in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 8 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application.Frontiers in immunology · 2025Pooled it
- Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysis.Radiation oncology (London, England) · 2024Pooled it
- Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.Frontiers in immunology · 2024Pooled it
- Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Pooled it
- Pooled it
- Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Efficacy and safety of stereotactic body radiotherapy for painful bone metastases: Evidence from randomized controlled trials.Frontiers in oncology · 2022Pooled it
- Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial.Molecular oncology · 2023Trial
- Omission of clinical target volume in radiotherapy for unresectable stage III non-small cell lung cancer: a propensity score matching analysis.Annals of medicine · 2026Article
- Low dose radiotherapy-induced tumor-preferential antigens enhance antibody-drug conjugate efficacy in solid tumors.Neoplasia (New York, N.Y.) · 2026Article
- Feasibility Study of Combined Systemic Therapy and Carbon-Ion Radiotherapy for Hepatocellular Carcinoma Patients.Cancer medicine · 2026Article
- Synergistic efficacy of radiotherapy and immunotherapy enhances clinical outcomes in patients with advanced non-small cell lung cancer.Discover oncology · 2026Article
- Enhanced efficacy of gastric cancer treatment by a combination of NK cells and chemotherapy.iScience · 2026Article
- Article
- Adapting federated radiomics models for radiation pneumonitis prediction in patients receiving thoracic radiotherapy with immunotherapy.Frontiers in immunology · 2026Article
- Data-driven precision: artificial intelligence redefining immunoradiotherapy in advanced pancreatic cancer.Frontiers in pharmacology · 2026Review
- Case Report: SMARCA4-deficient non-small cell lung cancer - effective local control with radiotherapy and emergence of a targetable EGFR mutation.Frontiers in oncology · 2026Article
- Respiratory adverse events associated with PD-1/PD-L1 inhibitors: an analysis based on the FDA adverse event reporting system.Frontiers in oncology · 2026Article
- Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study.Cancer pathogenesis and therapy · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA combination of programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors and radiotherapy (RT) is increasingly being used to treat non-small-cell lung cancer (NSCLC). However, the safety and efficacy of this approach remains controversial. We performed a systematic review and meta-analysis to summarize the related research.
methodsWe searched the China Biology Medicine, EMBASE, Cochrane Library, and PubMed databases for all the relevant studies. The Stata software, version 12.0 was used for the meta-analysis.
resultsThe study included 20 clinical trials that enrolled 2027 patients with NSCLC. Compared with non-combination therapy, combination therapy using PD-1/PD-L1 inhibitors and RT was associated with prolonged overall survival (OS) (1-year OS: odds ratio [OR] 1.77, 95% confidence interval [CI] 1.35-2.33, p = 0.000; 2-year OS: OR 1.77, 95% CI 1.35-2.33, p = 0.000) and progression-free survival (PFS) (0.5-year PFS: OR 1.83, 95% CI 1.13-2.98, p = 0.014; 1-year PFS: OR 2.09, 95% CI 1.29-3.38, p = 0.003; 2-year PFS: OR 2.47, 95% CI 1.13-5.37, p = 0.023). Combination therapy also improved the objective response rate (OR 2.76, 95% CI 1.06-7.19, p = 0.038) and disease control rate (OR 1.80, 95% CI 1.21-2.68, p = 0.004). This meta-analysis showed that compared with non-combination therapy, combination therapy using PD-1/PD-L1 inhibitors and RT did not increase the serious adverse event rates (≥grade 3); however, this approach increased the rate of grade 1-2 immune-related or radiation pneumonitis. Subgroup analyses revealed that the sequence of PD-1/PD-L1 inhibitors followed RT outperformed in which concurrent PD-1/PD-L1 inhibitor and RT followed PD-1/PD-L1 inhibitor. Combination of stereotactic body RT or stereotactic radiosurgery with PD-1/PD-L1 inhibitors may be more effective than a combination of conventional RT with PD-1/PD-L1 inhibitors in patients with advanced NSCLC.
conclusionCombination therapy using PD-1/PD-L1 inhibitors and RT may improve OS, PFS, and tumor response rates without an increase in serious adverse events in patients with advanced NSCLC. However, combination therapy was shown to increase the incidence of mild pneumonitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.